In a report released today, Tejas Savant from Morgan Stanley maintained a Hold rating on Abcam (ABCM – Research Report), with a price target of $20.00. The company's shares closed last Tuesday at $16.37, close to its 52-week low of $15.40. According to TipRanks.com, Savant 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -8.5% and a 33.9% success rate. Savant covers the Healthcare sector, focusing on stocks such as Ortho Clinical Diagnostics Holdings, Nautilus Biotechnolgy, and Akoya Biosciences. Abcam has an analyst consensus of Moderate Buy, with a price target consensus of $22.50.
https://www.tipranks.com/news/blurbs/morgan-stanley-reaffirms-their-hold-rating-on-abcam-abcm?utm_source=advfn.com&utm_medium=referral
Abcam (NASDAQ:ABCM)
Historical Stock Chart
From Jun 2022 to Jul 2022 Click Here for more Abcam Charts.
Abcam (NASDAQ:ABCM)
Historical Stock Chart
From Jul 2021 to Jul 2022 Click Here for more Abcam Charts.